

BioActive Human ATM oncogenic mutation Recombinant Protein,Fc Tag

Catalog Number:SGRP00658

DESCRIPTION	
Product Name	BioActive Human ATM oncogenic mutation Recombinant Protein,Fc Tag
Gene Name	ATM
Source	Full length Human ARID1A oncogenic mutation, expressed in HEK293 cells.
Alternative names	
SPECIFICATIONS	
Biological Activity	Fully biologically active
Purity	> 95% by SDS-PAGE & HPLC
Endotoxin Level	< 1.0 EU per µg protein as determined by the LAL method
Expression System	HEK293 Cells
Format	Recombinant
Species	Human
Predicted MW	
Actual MW	
Applications	Sandwich ELISA Functional Studies Mass Spectrometry SDS-PAGE HPLC
Form	Lyophilized from sterile PBS, pH 7.41
Concentration	N/A
Stability and Storage	Samples are stable for up to twelve months from date of receipt at -20°C to -80°C. Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution	Reconstitute with Phosphate Buffered Saline.
BACKGROUND	
Gene Accession	Q13315
Gene Alias	Protein names Recommended name Serine-protein kinase ATM EC number EC:2.7.11.1 6 Publications (UniProtKB ENZYME Rhea) Alternative names Ataxia telangiectasia mutated (A-T mutated) Gene names Name ATM

tumors. Such mutations may result in chemotherapy resistance and adverse prognosis, but may also be exploited by existing or emerging targeted therapies that produce synthetic lethal states.

Background

Germ-line mutations of the ataxia telangiectasia mutated (ATM) gene result in the well-characterized ataxia telangiectasia syndrome, which manifests with an increased cancer predisposition, including a 20% to 30% lifetime risk of lymphoid, gastric, breast, central nervous system, skin, and other cancers. Somatic ATM mutations or deletions are commonly found in lymphoid malignancies, as well as a variety of solid